Some weeks ago, we were made aware of an experimental drug trial targeting advanced solid mass tumours. With some input and coordination from Craig's oncologist, we were put in contact with an oncology research group, BeOne Medicines, via Te Whatu Ora in Auckland, who offered Craig a place in their human trial.
The drug, BG-C477, is an antibody-drug conjugate (ADC) composed of a humanised antibody that selectively targets carcinoembryonic antigen (CEA), coupled with a topoisomerase I (TOP1) inhibitor. CEA is present on the surface of cancer cells, meaning that the drug can bind specifically to cancer cells and release the TOP1 inhibitor payload, thereby blocking the activity of the TOP1 enzyme, essential for cell replication. The expected result is cell death to the targeted cells without harming the cells that are non-cancerous.
This is the first clinical trial of BG-C477 in humans with advanced solid tumours.
Given that all medicine thus far has been relatively inefficacious, it was worth a try. This is a unique situation where Craig can contribute data to cutting-edge research, giving back to the scientific community, while continuing to potentially benefiting from it. Craig agreed to take part, and the trial commenced shortly thereafter.
The goal is to at least stop the cancer getting worse. We have not received any results from the trial yet, but treatment continues, and our fingers are crossed for positive results.